{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:53:50Z","timestamp":1794671630023,"version":"4.9.1"},"reference-count":45,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,6,18]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the association between metformin treatment and the risk of neurodegenerative disease (ND) among elderly adults with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design\/Setting\/Participants<\/jats:title>\n                    <jats:p>This retrospective longitudinal cohort study examined the effects of the length of metformin exposure on ND among elderly US veterans with T2DM and insulin treatment using the Veterans Affairs electronic medical record database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary clinical outcome was defined as diagnosis of ND including dementia, Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD), Huntington\u2019s disease (HD) and mild cognitive impairment during the follow-up period. The secondary clinical outcomes were separately measured by AD, PD, HD, dementia and mild cognitive impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Adjusted by propensity score weight, a total of 5528 patients (mean age, 63.2\u00b110.9 years; male, 98%; white, 60%) with a median follow-up of 5.2 years were selected. Those with ND or other mental disorders at baseline or who were on insulin for less than two-thirds of the study period were excluded. The incidence rate of ND was 11.48 per 1000 person-years among patients with metformin treatment, compared with 25.45 per 1000 person-years for those without metformin. Compared with no metformin use, 2\u20134 years and &gt;4 years of metformin exposure were significantly associated with lower risk of ND (adjusted HR (aHR)=0.62, 95%\u2009CI 0.45 to 0.85; aHR=0.19, 95%\u2009CI 0.12 to 0.31, respectively), while metformin exposure in the first 2\u2009years showed no significant influence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We conclude that long-term metformin therapy (&gt;2 years) was associated with lower incidence of ND among elderly veterans with T2DM. We need to conduct a study with more representative population and more robust method for causal inferences. Further investigation into the mechanism involved is needed along with randomised trials to confirm a potential neuroprotective effect of metformin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-024954","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T06:25:15Z","timestamp":1564554315000},"page":"e024954","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":140,"title":["Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus"],"prefix":"10.1136","volume":"9","author":[{"given":"Qian","family":"Shi","sequence":"first","affiliation":[{"name":"Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA"},{"name":"Department of Endocrinology, Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina K","family":"Thethi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA"},{"name":"Department of Endocrinology, Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"2025121600132680000_9.7.e024954.1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828726f5"},{"key":"2025121600132680000_9.7.e024954.2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252807.38124.a3"},{"key":"2025121600132680000_9.7.e024954.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.01.009"},{"key":"2025121600132680000_9.7.e024954.4","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdu080"},{"key":"2025121600132680000_9.7.e024954.5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMsa1204629","article-title":"Monetary Costs of Dementia in the United States","volume":"368","author":"Hurd","year":"2013","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121600132680000_9.7.e024954.6","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12087"},{"key":"2025121600132680000_9.7.e024954.7","doi-asserted-by":"publisher","DOI":"10.1159\/000064928"},{"key":"2025121600132680000_9.7.e024954.8","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2006.42.11.1003542"},{"key":"2025121600132680000_9.7.e024954.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60360-2"},{"key":"2025121600132680000_9.7.e024954.10","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53480-4.00011-4"},{"key":"2025121600132680000_9.7.e024954.11","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1112"},{"key":"2025121600132680000_9.7.e024954.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2008.07.015"},{"key":"2025121600132680000_9.7.e024954.13","doi-asserted-by":"crossref","unstructured":"Moreira RO , Campos SC , Soldera AL . Type 2 Diabetes Mellitus and Alzheimer\u2019s Disease: from physiopathology to treatment implications. Diabetes Metab Res Rev 2013:n\/a.doi:10.1002\/dmrr.2442","DOI":"10.1002\/dmrr.2442"},{"key":"2025121600132680000_9.7.e024954.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2012.02758.x"},{"key":"2025121600132680000_9.7.e024954.15","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1588"},{"key":"2025121600132680000_9.7.e024954.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.03.010"},{"key":"2025121600132680000_9.7.e024954.17","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.27"},{"key":"2025121600132680000_9.7.e024954.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2011.01318.x"},{"key":"2025121600132680000_9.7.e024954.19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59903"},{"key":"2025121600132680000_9.7.e024954.20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1573399811309030003","article-title":"Alzheimer\u2019s disease and diabetes: new insights and unifying therapies","volume":"9","author":"Vignini","year":"2013","journal-title":"Curr Diabetes Rev"},{"key":"2025121600132680000_9.7.e024954.21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4239\/wjd.v6.i6.807","article-title":"Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide","volume":"6","author":"Candeias","year":"2015","journal-title":"World J Diabetes"},{"key":"2025121600132680000_9.7.e024954.22","doi-asserted-by":"publisher","DOI":"10.1042\/BST0331041"},{"key":"2025121600132680000_9.7.e024954.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03830.x"},{"key":"2025121600132680000_9.7.e024954.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"2025121600132680000_9.7.e024954.25","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"2025121600132680000_9.7.e024954.26","first-page":"54","article-title":"Metformin in the diabetic brain: friend or foe?","volume":"2","author":"Moreira","year":"2014","journal-title":"Ann Transl Med"},{"key":"2025121600132680000_9.7.e024954.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(10)70476-6"},{"key":"2025121600132680000_9.7.e024954.28","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1847"},{"key":"2025121600132680000_9.7.e024954.29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11064-009-0115-5","article-title":"Metformin normalizes type 2 diabetes-induced decrease in cell proliferation and neuroblast differentiation in the rat dentate gyrus","volume":"35","author":"Hwang","year":"2010","journal-title":"Neurochem Res"},{"key":"2025121600132680000_9.7.e024954.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.03.016"},{"key":"2025121600132680000_9.7.e024954.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-007-9002-1"},{"key":"2025121600132680000_9.7.e024954.32","doi-asserted-by":"publisher","DOI":"10.2174\/157340608784872299"},{"key":"2025121600132680000_9.7.e024954.33","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-131901"},{"key":"2025121600132680000_9.7.e024954.34","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-101524"},{"key":"2025121600132680000_9.7.e024954.35","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0229"},{"key":"2025121600132680000_9.7.e024954.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.03916.x"},{"key":"2025121600132680000_9.7.e024954.37","first-page":"277","article-title":"Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer\u2019s disease","volume":"16","author":"Alagiakrishnan","year":"2013","journal-title":"Discov Med"},{"key":"2025121600132680000_9.7.e024954.38","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer\u2019s-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"2025121600132680000_9.7.e024954.39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/CIA.S74042","article-title":"Link between type 2 diabetes and Alzheimer\u2019s disease: from epidemiology to mechanism and treatment","volume":"10","author":"Li","year":"2015","journal-title":"Clin Interv Aging"},{"key":"2025121600132680000_9.7.e024954.40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.1937"},{"key":"2025121600132680000_9.7.e024954.41","doi-asserted-by":"publisher","DOI":"10.1177\/2040622316657328"},{"key":"2025121600132680000_9.7.e024954.42","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.02.06.dc05-1626"},{"key":"2025121600132680000_9.7.e024954.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.07.033"},{"key":"2025121600132680000_9.7.e024954.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.07.055"},{"key":"2025121600132680000_9.7.e024954.45","doi-asserted-by":"crossref","unstructured":"James M , Robins MAH . Estimation of the causal effects of time-varying exposures. Longitudinal Data Analysis 2009:576.","DOI":"10.1201\/9781420011579.ch23"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-024954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:13:34Z","timestamp":1765872814000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-024954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,30]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bmjopen-2018-024954"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-024954","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2018-024954.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}